Ambien (Zolpidem): Dependence, Withdrawal, and Recovery Support

Ambien (zolpidem) is the most widely used prescription sleeping pill in the United States. In 2011, two years before the FDA cut the recommended dose for women in half, "about 39 million prescriptions for zolpidem products were dispensed, and about 9 million patients received zolpidem products" (FDA, 2013). For many people it is an occasional pill; for others it becomes the only way they know how to fall asleep, the dose creeps up, and stopping feels impossible. This page covers how zolpidem works, how dependence differs from addiction, what withdrawal looks like, why a taper beats stopping cold, what treats the insomnia underneath, and how support at home fits in.

What Ambien is and how it works

Zolpidem is a sedative-hypnotic approved "for the short-term treatment of insomnia characterized by difficulties with sleep initiation" (Ambien prescribing information, section 1). It is also sold as Ambien CR (extended-release, also approved for staying asleep), Edluar, Zolpimist, and generic zolpidem tartrate (Ambien CR prescribing information, section 1). Street slang ("zombie pills," "A-minus") is thin; most people just say Ambien. It is a Schedule IV controlled substance (section 9.1), the same schedule as Xanax and Valium.

Zolpidem is not chemically a benzodiazepine, which is why it, eszopiclone (Lunesta), and zaleplon (Sonata) are called "Z-drugs," but it works at the same place. The label calls it "a GABA A receptor positive modulator" acting through "binding to the benzodiazepine site of α1 subunit containing GABA A receptors" (section 12.1). The 2025 ASAM joint benzodiazepine tapering guideline left Z-drugs out of scope but noted they "have similar mechanisms of action to BZDs and may pose similar risks" (ASAM, 2025).

The other defining feature is speed. The label reports a mean elimination half-life of "2.6 (range: 1.4 to 4.5) and 2.5 (range: 1.4 to 3.8) hours, for the 5 and 10 mg tablets, respectively" (section 12.3), and about 2.8 hours for Ambien CR (Ambien CR, section 12.3). That is what makes it a sleeping pill rather than a tranquilizer, and what makes the effect feel like a switch, which is easy to lean on.

Dependence, misuse, and addiction are not the same thing

The label draws these lines clearly. "Use of AMBIEN may lead to the development of physical and/or psychological dependence. The risk of dependence increases with dose and duration of treatment," and dependence "is a state of adaptation that is manifested by a specific withdrawal syndrome" when the drug is stopped or cut quickly (section 9.3). Someone who has taken 10 mg nightly for three years on a valid prescription is very likely dependent. That is pharmacology, and it happens to people who never took an extra pill.

The label continues: "Abuse and addiction are separate and distinct from physical dependence and tolerance. Abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances." Addiction "is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving" (section 9.2). Misuse with zolpidem has a recognizable shape: taking it early and staying up to ride the loose, sometimes euphoric window before sleep wins; doubling up because 10 mg "stopped working." An analysis of the European Medicines Agency's adverse reaction database found zolpidem "the most frequently reported" Z-drug for misuse and dependence, with doses above 100 mg in more than 6,000 reports (Schifano et al., Int J Neuropsychopharmacol, 2019).

The label also names who is most at risk: "persons with a history of addiction to, or abuse of, drugs or alcohol are at increased risk for misuse, abuse and addiction of zolpidem" (section 9.2). We see this constantly: a member with years of sobriety gets a sleeping pill after a surgery, nobody asks about their history, and the old wiring lights up.

Signs Ambien has become a problem

Families and members describe a consistent picture. The dose has gone up, or a 30-day supply runs out in three weeks. The person cannot imagine sleeping without it and counts pills in the late afternoon. There are gaps: texts, calls, or online orders they do not remember from the hour after the pill; the label notes evidence of "anterograde amnesia occurring in association with the administration of AMBIEN, predominantly at doses above 10 mg" (section 5.5). Someone found food wrappers in the bed or the car parked crooked. The pill is taken earlier each evening and sleep is fought rather than allowed. It gets combined with a drink. Any one of these is worth a conversation with the prescriber. Several together are worth a call to us.

On April 30, 2019, the FDA required a boxed warning on all three Z-drugs for "complex sleep behaviors" such as "sleepwalking, sleep driving, and engaging in other activities while not fully awake." It had identified 66 cases of serious injury or death, 20 of them fatal, including falls, burns, near drowning, and "motor vehicle collisions with the patient driving." They occurred "even at the lowest recommended doses," and "can occur after just one dose" (FDA, 2019). The label now says to "Discontinue AMBIEN immediately if a patient experiences a complex sleep behavior" (boxed warning). If someone in your house has done something on Ambien that they do not remember, that is a stop sign, not a quirk.

Is stopping Ambien dangerous?

Honest answer: usually not, and sometimes yes. On a prescribed dose, stopping usually brings a rough night or two and some anxiety, not a medical emergency. The immediate-release label reports "no objective (polysomnographic) evidence of rebound insomnia at recommended doses" (section 14.3), and the Ambien CR label says "A rebound effect was only observed on the first night after abrupt discontinuation" (section 14.2). Members tell us the first night is worse than the studies suggest, and we believe them.

The picture changes with dose and duration. The same label warns of "withdrawal signs and symptoms following the rapid dose decrease or abrupt discontinuation of zolpidem" (section 5.9) and puts it with every other sedative: symptoms "range from mild dysphoria and insomnia to a withdrawal syndrome that may include abdominal and muscle cramps, vomiting, sweating, tremors, convulsions, and delirium" (section 9.3). The European review ties Z-drug withdrawal to "abrupt cessation of long-term, high-dosage intake" and lists "tonic-clonic seizures" among the symptoms (Schifano et al., 2019). If you take 20, 40, or 100 mg a night, or combine zolpidem with alcohol or a benzodiazepine, treat stopping the way you would treat stopping Xanax: with a prescriber, on a schedule, not on a Friday night because the bottle ran out.

Ambien withdrawal timeline

Everyone differs. The biggest variables are dose, years of use, whether alcohol or benzodiazepines are on board, and whether the underlying insomnia was ever treated.

First night or two

Rebound insomnia is the headline. You lie awake and the belief that you "cannot sleep without it" feels confirmed. Sweating, restlessness, and a racing heart are common. For someone on a high dose who stopped abruptly, this is the window where tremor, confusion, and, rarely, seizures appear (section 9.3), which is why that person should not be doing this alone.

Days 2 to 7

Sleep returns in fragments. Anxiety, irritability, low mood, and vivid dreams are the main complaints. This is where people go back "just for one night," which resets the clock.

Weeks 2 to 4

Most people are sleeping, not well but sleeping. What remains is the original insomnia plus the habits built around the pill: dread at bedtime, clock-watching, 3 a.m. bargaining. This is what CBT-I treats, and where a coach earns their keep.

Beyond a month

People who took high doses for years sometimes describe weeks of poor sleep and low mood. The label notes that "The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness" (section 5.3); if sleep is still terrible a month out, something else is driving it.

How treatment works

There is no FDA-approved medication for zolpidem dependence. Treatment has two parts: come off the drug safely, and treat the insomnia that started it.

The first part is a taper planned with the prescriber. The Ambien label publishes no schedule and the ASAM guideline leaves Z-drugs out (ASAM, 2025), so prescribers borrow its logic: small steps, a pause when symptoms spike, no deadline. Someone on 10 mg might drop to 5 mg for two weeks, then every other night, then off. Someone on 40 mg, four times the labeled maximum (section 2.1), needs a longer plan and possibly a higher level of care.

The second part is cognitive behavioral therapy for insomnia, CBT-I. The 2025 VA/DoD clinical practice guideline gives it the strongest rating available, "we recommend treatment with CBT-I" (Strong for), and puts it ahead of medication as first-line treatment; zolpidem itself earns a "Weak for" as one of several options for people offered a course of medication (VA/DoD, 2025, Recommendations 5 and 9). Its pieces are sleep restriction, which "Limits time in bed to actual sleep duration to increase sleep drive," stimulus control, relaxation, and cognitive restructuring (VA/DoD full guideline, Sidebar 3). It is available by telehealth. Do not let "I tried sleep hygiene" stand in for it; sleep hygiene is one small piece of CBT-I.

Older adults carry a large share of the harm; people "aged 65 or older represented 32%" of emergency visits for adverse reactions to zolpidem in 2010 (SAMHSA DAWN, 2013). The label sets the geriatric dose at 5 mg and warns that "patients, particularly the elderly, are at higher risk of falls" (sections 8.5 and 5.2). The 2023 Beers Criteria say to avoid Z-drugs in older adults altogether: "adverse events similar to those of benzodiazepines in older adults (e.g., delirium, falls, fractures, increased emergency room visits/hospitalizations, motor vehicle crashes); minimal improvement in sleep latency and duration" (AGS Beers Criteria, 2023).

Ambien with alcohol, opioids, or benzodiazepines

Zolpidem on its own rarely kills. In combination it can. The label warns that "Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression" and that "The concomitant use of AMBIEN with opioids may increase the risk of respiratory depression" (sections 5.2 and 7.1).

When the FDA added its strongest warning to opioid and benzodiazepine labels in 2016, it framed the danger as opioids "along with benzodiazepines or other central nervous system (CNS) depressant medicines, including alcohol," with risks that "include extreme sleepiness, respiratory depression, coma and death" (FDA, 2016). A sleeping pill is a CNS depressant. Of roughly 20,800 zolpidem-related emergency visits in 2010 attributed to taking too much, 57 percent involved other substances, including narcotic pain relievers (25 percent) and alcohol (14 percent), and "Nearly half (47 percent)" ended in "a hospital admission or transfer" (SAMHSA DAWN, 2014). If someone you love takes Ambien and any opioid, keep naloxone in the house; it reverses the opioid part only, which is the part most likely to stop their breathing.

Complex sleep behaviors "may occur with AMBIEN alone at recommended doses, with or without the concomitant use of alcohol" (section 5.1), but in our experience the sleep-driving stories almost always include a nightcap. Next-morning driving is its own hazard. The FDA found that eight hours after a 10 mg dose, "about 15% of women and 3% of men had zolpidem concentrations that exceeded 50 ng/mL," the level linked to impaired driving, and warned that people "can experience impairment of mental alertness the morning after use, even if they feel fully awake" (FDA, January 2013). That is why the starting dose for women was cut to 5 mg and why people taking Ambien CR "should not drive or engage in other activities that require complete mental alertness the day after" (FDA, May 2013).

Drug testing for Ambien

Zolpidem is invisible to most routine drug screens. It is not a benzodiazepine, so the benzodiazepine line on a standard panel does not react to it, and a negative test from work or court says nothing about Ambien unless zolpidem is on the panel by name.

Saliva windows are short and depend on the cutoff. In one controlled study, 14 volunteers took a single 10 mg tablet; zolpidem was detectable in oral fluid within an hour, peaked near 37 ng/mL at two hours, and cleared with an oral fluid half-life of about 2.8 hours (Feng et al., Drug Test Anal, 2019). At a 2 ng/mL cutoff, that puts a single dose at roughly half a day of detectability; nightly or high-dose use extends it, and we would rather not quote one number for everyone. A prescribed, tapering dose will test positive the next morning; what matters is whether the result matches the plan.

Our members use saliva-based screening that is assigned at random through the week. Zolpidem is not on the instant 10-panel strip we use, so for a member whose plan involves Ambien, screening is run as the lab-confirmed oral fluid test, which reports zolpidem by name at a 2 ng/mL cutoff, confirmed by LC-MS/MS at a CLIA-certified lab. You do not choose whether you test; you choose who sees the results. For most members that means the prescriber managing the taper and, if they want, a spouse or parent. We explain the details in our guide to how sobriety monitoring works.

How recovery from Ambien works with Accountable

We are not a detox and we do not prescribe. The taper belongs to your doctor and CBT-I to a therapist trained in it. What we provide is the structure around both, at home, for as long as you need it.

1. Get the full picture

In the first sessions your coach maps what is actually going on: how many milligrams, for how many years, whether you take it early and stay up, what the memory gaps look like, and whether alcohol, benzodiazepines, or opioids are in the picture. We ask about your history with other substances, because zolpidem finds old grooves. If you do not have a prescriber managing a taper, or a CBT-I provider, we help you find both, and with your permission we coordinate so everyone works from the same plan.

2. Build a plan that fits your life

Insomnia recovery lives at 2 a.m., so that is where the plan has to work. Your coach helps you decide in advance what you will do on the nights the taper steps down: who you text, what you do instead of lying in bed, how you get through the next workday. During CBT-I, your coach helps you stick with sleep restriction through the weeks it feels like it is making things worse. Daily peer group meetings and a weekly family Zoom group give you and the people around you somewhere to go.

3. Weekly check-ins through the long stretch

The risky weeks are three through eight, when the pills are gone, sleep is mediocre, and the old bottle starts to look reasonable. Your coach shows up every week, and the lab-confirmed saliva screening turns "I think I'm doing okay" into a shared record that you control. When a return to use happens, we treat it as information: the plan changes and the support goes up. Every coach at Accountable has their own recovery behind them.

Accountable is covered by a growing list of commercial health plans, with more added each month, and private-pay plans start at $375 per month. You can check your coverage in a few minutes or call the care team at (646) 450-7641. Families are welcome to make the first call; see our page for families.

Common questions

How long does Ambien stay in your system?

Not long. The half-life is about 2.5 hours for Ambien and 2.8 hours for Ambien CR (Ambien, section 12.3; Ambien CR, section 12.3), so most of a single dose is gone within a day, and in saliva a 10 mg dose peaks about two hours in and falls with a half-life near 2.8 hours (Feng et al., 2019).

How long does Ambien withdrawal last?

On a prescribed dose, the worst is the first night or two of rebound insomnia (Ambien CR, section 14.2), with anxiety and broken sleep easing over one to two weeks. Higher doses and longer use mean a longer course; a taper keeps it milder. Insomnia still severe a month later is usually the original problem returning (Ambien, section 5.3).

Can I just stop taking Ambien?

Many people on 5 or 10 mg can stop with a short step-down and a plan for the first bad nights, but talk to your prescriber first. If you take more than the labeled maximum, have taken it for years, or also drink or take benzodiazepines, do not stop abruptly. The label lists tremors, convulsions, and delirium among reported sedative-hypnotic withdrawal symptoms after abrupt discontinuation (section 9.3).

Does Ambien show up on a drug test?

Not on a standard panel; it needs its own assay. Our instant 10-panel strip does not include it, so members whose plan involves zolpidem are screened with the lab-confirmed oral fluid test, which reports it at a 2 ng/mL cutoff.

What should I do if someone on Ambien will not wake up?

Call 911. If there is any chance opioids are involved, give naloxone; it does no harm if they are not. Keep the person on their side and stay with them. The label reports overdoses "ranging from somnolence to coma, cardiovascular and/or respiratory compromise, and fatal outcomes," alone or with other CNS depressants (section 10).

Sources

• U.S. Food and Drug Administration. Ambien (zolpidem tartrate) tablets, prescribing information, revised February 2022.

• U.S. Food and Drug Administration. Ambien CR (zolpidem tartrate extended-release) tablets, prescribing information, revised February 2022.

• U.S. Food and Drug Administration. FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines. Drug Safety Communication, April 30, 2019.

• U.S. Food and Drug Administration. Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). Drug Safety Communication, January 10, 2013.

• U.S. Food and Drug Administration. FDA approves new label changes and dosing for zolpidem products and a recommendation to avoid driving the day after using Ambien CR. Drug Safety Communication, May 14, 2013.

• U.S. Food and Drug Administration. New Safety Measures Announced for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepines. August 31, 2016.

• U.S. Department of Veterans Affairs and U.S. Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea, Provider Summary. Version 3.0, 2025.

• U.S. Department of Veterans Affairs and U.S. Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea, full guideline. Version 3.0, 2025.

• American Society of Addiction Medicine. Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (full guideline PDF), 2025.

• 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2023;71(7):2052-2081.

• Schifano F, Chiappini S, Corkery JM, Guirguis A. An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. International Journal of Neuropsychopharmacology. 2019;22(4):270-277.

• Feng X, Chen H, Xiang P, Shen M. Zolpidem and zolpidem phenyl-4-carboxylic acid pharmacokinetics in oral fluid after a single dose. Drug Testing and Analysis. 2019;11(7):1076-1082.

• Substance Abuse and Mental Health Services Administration. The DAWN Report: Emergency Department Visits Attributed to Overmedication That Involved the Insomnia Medication Zolpidem. August 7, 2014.

• Substance Abuse and Mental Health Services Administration. The DAWN Report: Emergency Department Visits for Adverse Reactions Involving the Insomnia Medication Zolpidem. May 1, 2013, NCBI Bookshelf.